We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+40.06%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
+$164M
Cap. Flow
+$47.9M
Cap. Flow %
3.88%
Top 10 Hldgs %
53.52%
Holding
82
New
29
Increased
10
Reduced
10
Closed
25

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$49M
2
IMCR icon
Immunocore
IMCR
+$34.3M
3
CLDX icon
Celldex Therapeutics
CLDX
+$26.7M
4
SLN
Silence Therapeutics
SLN
+$23.4M
5
ADVM
Adverum Biotechnologies
ADVM
+$22.8M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$118M
2
ARGX icon
argenx
ARGX
+$55.2M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$35.3M
4
AMAM
Ambrx Biopharma Inc
AMAM
+$29.9M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.89%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MOR
76
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-1,475,000
Closed -$14.6M
KRTX
77
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-90,000
Closed -$28.5M
AMAM
78
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-2,100,000
Closed -$29.9M
RYZB
79
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-568,173
Closed -$35.3M
ICVX
80
DELISTED
Icosavax, Inc. Common Stock
ICVX
– –
-300,000
Closed -$4.73M
INBX
81
CALL
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-500,000
Closed -$19M
INBX
82
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-100,000
Closed -$3.8M
1 2 3
4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2024 Portfolio in Review

As of Q1 2024, Logos Global Management held 82 positions worth $1.24B, up 15% from $1.07B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Logos Global Management deployed $47.9M of net new capital in Q1 2024, opening 29 new positions and adding to 10 existing holdings. Its largest new stake was Sarepta Therapeutics: 400,000 shares worth $51.8M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 84% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Cytokinetics, an estimated $118M trimmed.

  • Logos Global Management's largest Q1 2024 buy was Sarepta Therapeutics: 400,000 shares worth $51.8M.
  • Logos Global Management added most to Immunocore in Q1 2024, an estimated $34.3M increase.
  • Logos Global Management's biggest Q1 2024 reduction was Cytokinetics, cutting an estimated $118M.
  • Logos Global Management fully exited argenx in Q1 2024, selling an estimated $55.2M.
  • Logos Global Management's ten largest holdings make up 54% of its $1.24B portfolio in Q1 2024.
  • Logos Global Management opened 29 new positions and closed 25 in Q1 2024.
  • Logos Global Management's portfolio value rose 15% quarter-over-quarter to $1.24B.

Based on Logos Global Management's 13F filing for Q1 2024, filed 15 May 2024.